Dual route vaccination for plague with emergency use applications

B. D. Moore, R. R.C. New, W. Butcher, R. Mahood, J. Steward, M. Bayliss, C. MacLeod, M. Bogus, E. D. Williamson

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Here, we report a dual-route vaccination approach for plague, able to induce a rapid response involving systemic and mucosal immunity, whilst also providing ease of use in those resource-poor settings most vulnerable to disease outbreaks. This novel vaccine (VypVaxDuo) comprises the recombinant F1 and V proteins in free association. VypVaxDuo has been designed for administration via a sub-cutaneous priming dose followed by a single oral booster dose and has been demonstrated to induce early onset immunity 14 days after the primary immunisation; full protective efficacy against live organism challenge was achieved in Balb/c mice exposed to 2 × 104 median lethal doses of Yersinia pestis Co92, by the sub-cutaneous route at 25 days after the oral booster immunisation. This dual-route vaccination effectively induced serum IgG and serum and faecal IgA, specific for F1 and V, which constitute two key virulence factors in Y. pestis, and is therefore suitable for further development to prevent bubonic plague and for evaluation in models of pneumonic plague. This is an essential requirement for control of disease outbreaks in areas of the world endemic for plague and is supported further by the observed exceptional stability of the primary vaccine formulation in vialled form under thermostressed conditions (40 °C for 29 weeks, and 40 °C with 75% relative humidity for 6 weeks), meaning no cold chain for storage or distribution is needed. In clinical use, the injected priming dose would be administered on simple rehydration of the dry powder by means of a dual barrel syringe, with the subsequent single booster dose being provided in an enteric-coated capsule suitable for oral self-administration.

LanguageEnglish
Pages5210-5217
Number of pages8
JournalVaccine
Volume36
Issue number34
Early online date14 Jul 2018
DOIs
Publication statusPublished - 16 Aug 2018

Fingerprint

Plague
plague
Vaccination
Emergencies
vaccination
Yersinia pestis
dosage
Disease Outbreaks
mouth
Vaccine Potency
Free Association
vaccines
mucosal immunity
Secondary Immunization
oral vaccination
fluid therapy
Mucosal Immunity
Refrigeration
Skin
Self Administration

Keywords

  • dual route
  • emergency use
  • mucosal
  • plague
  • protection
  • systemic
  • vaccine

Cite this

Moore, B. D., New, R. R. C., Butcher, W., Mahood, R., Steward, J., Bayliss, M., ... Williamson, E. D. (2018). Dual route vaccination for plague with emergency use applications. Vaccine, 36(34), 5210-5217. https://doi.org/10.1016/j.vaccine.2018.06.039
Moore, B. D. ; New, R. R.C. ; Butcher, W. ; Mahood, R. ; Steward, J. ; Bayliss, M. ; MacLeod, C. ; Bogus, M. ; Williamson, E. D. / Dual route vaccination for plague with emergency use applications. In: Vaccine. 2018 ; Vol. 36, No. 34. pp. 5210-5217.
@article{a20ee6fa845d4ee7827e8eb1866648be,
title = "Dual route vaccination for plague with emergency use applications",
abstract = "Here, we report a dual-route vaccination approach for plague, able to induce a rapid response involving systemic and mucosal immunity, whilst also providing ease of use in those resource-poor settings most vulnerable to disease outbreaks. This novel vaccine (VypVaxDuo) comprises the recombinant F1 and V proteins in free association. VypVaxDuo has been designed for administration via a sub-cutaneous priming dose followed by a single oral booster dose and has been demonstrated to induce early onset immunity 14 days after the primary immunisation; full protective efficacy against live organism challenge was achieved in Balb/c mice exposed to 2 × 104 median lethal doses of Yersinia pestis Co92, by the sub-cutaneous route at 25 days after the oral booster immunisation. This dual-route vaccination effectively induced serum IgG and serum and faecal IgA, specific for F1 and V, which constitute two key virulence factors in Y. pestis, and is therefore suitable for further development to prevent bubonic plague and for evaluation in models of pneumonic plague. This is an essential requirement for control of disease outbreaks in areas of the world endemic for plague and is supported further by the observed exceptional stability of the primary vaccine formulation in vialled form under thermostressed conditions (40 °C for 29 weeks, and 40 °C with 75{\%} relative humidity for 6 weeks), meaning no cold chain for storage or distribution is needed. In clinical use, the injected priming dose would be administered on simple rehydration of the dry powder by means of a dual barrel syringe, with the subsequent single booster dose being provided in an enteric-coated capsule suitable for oral self-administration.",
keywords = "dual route, emergency use, mucosal, plague, protection, systemic, vaccine",
author = "Moore, {B. D.} and New, {R. R.C.} and W. Butcher and R. Mahood and J. Steward and M. Bayliss and C. MacLeod and M. Bogus and Williamson, {E. D.}",
year = "2018",
month = "8",
day = "16",
doi = "10.1016/j.vaccine.2018.06.039",
language = "English",
volume = "36",
pages = "5210--5217",
journal = "Vaccine",
issn = "0264-410X",
number = "34",

}

Moore, BD, New, RRC, Butcher, W, Mahood, R, Steward, J, Bayliss, M, MacLeod, C, Bogus, M & Williamson, ED 2018, 'Dual route vaccination for plague with emergency use applications' Vaccine, vol. 36, no. 34, pp. 5210-5217. https://doi.org/10.1016/j.vaccine.2018.06.039

Dual route vaccination for plague with emergency use applications. / Moore, B. D.; New, R. R.C.; Butcher, W.; Mahood, R.; Steward, J.; Bayliss, M.; MacLeod, C.; Bogus, M.; Williamson, E. D.

In: Vaccine, Vol. 36, No. 34, 16.08.2018, p. 5210-5217.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Dual route vaccination for plague with emergency use applications

AU - Moore, B. D.

AU - New, R. R.C.

AU - Butcher, W.

AU - Mahood, R.

AU - Steward, J.

AU - Bayliss, M.

AU - MacLeod, C.

AU - Bogus, M.

AU - Williamson, E. D.

PY - 2018/8/16

Y1 - 2018/8/16

N2 - Here, we report a dual-route vaccination approach for plague, able to induce a rapid response involving systemic and mucosal immunity, whilst also providing ease of use in those resource-poor settings most vulnerable to disease outbreaks. This novel vaccine (VypVaxDuo) comprises the recombinant F1 and V proteins in free association. VypVaxDuo has been designed for administration via a sub-cutaneous priming dose followed by a single oral booster dose and has been demonstrated to induce early onset immunity 14 days after the primary immunisation; full protective efficacy against live organism challenge was achieved in Balb/c mice exposed to 2 × 104 median lethal doses of Yersinia pestis Co92, by the sub-cutaneous route at 25 days after the oral booster immunisation. This dual-route vaccination effectively induced serum IgG and serum and faecal IgA, specific for F1 and V, which constitute two key virulence factors in Y. pestis, and is therefore suitable for further development to prevent bubonic plague and for evaluation in models of pneumonic plague. This is an essential requirement for control of disease outbreaks in areas of the world endemic for plague and is supported further by the observed exceptional stability of the primary vaccine formulation in vialled form under thermostressed conditions (40 °C for 29 weeks, and 40 °C with 75% relative humidity for 6 weeks), meaning no cold chain for storage or distribution is needed. In clinical use, the injected priming dose would be administered on simple rehydration of the dry powder by means of a dual barrel syringe, with the subsequent single booster dose being provided in an enteric-coated capsule suitable for oral self-administration.

AB - Here, we report a dual-route vaccination approach for plague, able to induce a rapid response involving systemic and mucosal immunity, whilst also providing ease of use in those resource-poor settings most vulnerable to disease outbreaks. This novel vaccine (VypVaxDuo) comprises the recombinant F1 and V proteins in free association. VypVaxDuo has been designed for administration via a sub-cutaneous priming dose followed by a single oral booster dose and has been demonstrated to induce early onset immunity 14 days after the primary immunisation; full protective efficacy against live organism challenge was achieved in Balb/c mice exposed to 2 × 104 median lethal doses of Yersinia pestis Co92, by the sub-cutaneous route at 25 days after the oral booster immunisation. This dual-route vaccination effectively induced serum IgG and serum and faecal IgA, specific for F1 and V, which constitute two key virulence factors in Y. pestis, and is therefore suitable for further development to prevent bubonic plague and for evaluation in models of pneumonic plague. This is an essential requirement for control of disease outbreaks in areas of the world endemic for plague and is supported further by the observed exceptional stability of the primary vaccine formulation in vialled form under thermostressed conditions (40 °C for 29 weeks, and 40 °C with 75% relative humidity for 6 weeks), meaning no cold chain for storage or distribution is needed. In clinical use, the injected priming dose would be administered on simple rehydration of the dry powder by means of a dual barrel syringe, with the subsequent single booster dose being provided in an enteric-coated capsule suitable for oral self-administration.

KW - dual route

KW - emergency use

KW - mucosal

KW - plague

KW - protection

KW - systemic

KW - vaccine

U2 - 10.1016/j.vaccine.2018.06.039

DO - 10.1016/j.vaccine.2018.06.039

M3 - Article

VL - 36

SP - 5210

EP - 5217

JO - Vaccine

T2 - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 34

ER -

Moore BD, New RRC, Butcher W, Mahood R, Steward J, Bayliss M et al. Dual route vaccination for plague with emergency use applications. Vaccine. 2018 Aug 16;36(34):5210-5217. https://doi.org/10.1016/j.vaccine.2018.06.039